Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...

UBS analyst Matthew Weston downgraded Novartis (SIX:NOVN) shares from Buy to Neutral and reduced the price target from CHF111 ...

In a report released today, Matthew Weston from UBS downgraded Novartis AG (NOVN – Research Report) to a Hold, with a price target of ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Nestle's slumping share price is rattling shareholders and pension funds that have invested in the food giant, piling ...

Novartis (NYSE:NVS – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating ...